BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33493488)

  • 1. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.
    Schrijver LH; Antoniou AC; Olsson H; Mooij TM; Roos-Blom MJ; Azarang L; Adlard J; Ahmed M; Barrowdale D; Davidson R; Donaldson A; Eeles R; Evans DG; Frost D; Henderson A; Izatt L; Ong KR; Bonadona V; Coupier I; Faivre L; Fricker JP; Gesta P; van Engelen K; Jager A; Menko FH; Mourits MJE; Singer CF; Tan YY; Foretova L; Navratilova M; Schmutzler RK; Ellberg C; Gerdes AM; Caldes T; Simard J; Olah E; Jakubowska A; Rantala J; Osorio A; Hopper JL; Phillips KA; Milne RL; Beth Terry M; Noguès C; Engel C; Kast K; Goldgar DE; van Leeuwen FE; Easton DF; Andrieu N; Rookus MA;
    Am J Obstet Gynecol; 2021 Jul; 225(1):51.e1-51.e17. PubMed ID: 33493488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.
    Antoniou AC; Rookus M; Andrieu N; Brohet R; Chang-Claude J; Peock S; Cook M; Evans DG; Eeles R; ; Nogues C; Faivre L; Gesta P; ; van Leeuwen FE; Ausems MG; Osorio A; ; Caldes T; Simard J; Lubinski J; Gerdes AM; Olah E; Fürhauser C; Olsson H; Arver B; Radice P; Easton DF; Goldgar DE
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):601-10. PubMed ID: 19190154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
    Mavaddat N; Peock S; Frost D; Ellis S; Platte R; Fineberg E; Evans DG; Izatt L; Eeles RA; Adlard J; Davidson R; Eccles D; Cole T; Cook J; Brewer C; Tischkowitz M; Douglas F; Hodgson S; Walker L; Porteous ME; Morrison PJ; Side LE; Kennedy MJ; Houghton C; Donaldson A; Rogers MT; Dorkins H; Miedzybrodzka Z; Gregory H; Eason J; Barwell J; McCann E; Murray A; Antoniou AC; Easton DF;
    J Natl Cancer Inst; 2013 Jun; 105(11):812-22. PubMed ID: 23628597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
    Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
    N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Kotsopoulos J; Gronwald J; McCuaig JM; Karlan BY; Eisen A; Tung N; Bordeleau L; Senter L; Eng C; Couch F; Fruscio R; Weitzel JN; Olopade O; Singer CF; Pal T; Foulkes WD; Neuhausen SL; Sun P; Lubinski J; Narod SA;
    Gynecol Oncol; 2020 Dec; 159(3):820-826. PubMed ID: 33010967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
    Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.
    van Bommel MHD; IntHout J; Veldmate G; Kets CM; de Hullu JA; van Altena AM; Harmsen MG
    Hum Reprod Update; 2023 Mar; 29(2):197-217. PubMed ID: 36383189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
    Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Gronwald J; Cybulski C; Demsky R; Neuhausen SL; Kim-Sing C; Tung N; Friedman S; Senter L; Weitzel J; Karlan B; Moller P; Sun P; Narod SA;
    Int J Cancer; 2015 Sep; 137(5):1136-46. PubMed ID: 25482078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
    Schrijver LH; Mooij TM; Pijpe A; Sonke GS; Mourits MJE; Andrieu N; Antoniou AC; Easton DF; Engel C; Goldgar D; John EM; Kast K; Milne RL; Olsson H; Phillips KA; Terry MB; Hopper JL; van Leeuwen FE; Rookus MA
    J Natl Cancer Inst; 2022 Apr; 114(4):540-552. PubMed ID: 35048954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.
    Friebel TM; Domchek SM; Rebbeck TR
    J Natl Cancer Inst; 2014 Jun; 106(6):dju091. PubMed ID: 24824314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies.
    Park J; Huang D; Chang YJ; Lim MC; Myung SK
    Carcinogenesis; 2022 Apr; 43(3):231-242. PubMed ID: 34958358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50.
    Haile RW; Thomas DC; McGuire V; Felberg A; John EM; Milne RL; Hopper JL; Jenkins MA; Levine AJ; Daly MM; Buys SS; Senie RT; Andrulis IL; Knight JA; Godwin AK; Southey M; McCredie MR; Giles GG; Andrews L; Tucker K; Miron A; Apicella C; Tesoriero A; Bane A; Pike MC; ; ; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1863-70. PubMed ID: 17021353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.
    Moorman PG; Havrilesky LJ; Gierisch JM; Coeytaux RR; Lowery WJ; Peragallo Urrutia R; Dinan M; McBroom AJ; Hasselblad V; Sanders GD; Myers ER
    J Clin Oncol; 2013 Nov; 31(33):4188-98. PubMed ID: 24145348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.
    Brohet RM; Goldgar DE; Easton DF; Antoniou AC; Andrieu N; Chang-Claude J; Peock S; Eeles RA; Cook M; Chu C; Noguès C; Lasset C; Berthet P; Meijers-Heijboer H; Gerdes AM; Olsson H; Caldes T; van Leeuwen FE; Rookus MA
    J Clin Oncol; 2007 Sep; 25(25):3831-6. PubMed ID: 17635951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.
    Narod SA; Risch H; Moslehi R; Dørum A; Neuhausen S; Olsson H; Provencher D; Radice P; Evans G; Bishop S; Brunet JS; Ponder BA
    N Engl J Med; 1998 Aug; 339(7):424-8. PubMed ID: 9700175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
    Eoh KJ; Park EY; Chang YJ; Ha HI; Hong J; Huang D; Nam EJ; Lim MC
    Gynecol Oncol; 2021 Oct; 163(1):142-147. PubMed ID: 34304906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Narod SA; Dubé MP; Klijn J; Lubinski J; Lynch HT; Ghadirian P; Provencher D; Heimdal K; Moller P; Robson M; Offit K; Isaacs C; Weber B; Friedman E; Gershoni-Baruch R; Rennert G; Pasini B; Wagner T; Daly M; Garber JE; Neuhausen SL; Ainsworth P; Olsson H; Evans G; Osborne M; Couch F; Foulkes WD; Warner E; Kim-Sing C; Olopade O; Tung N; Saal HM; Weitzel J; Merajver S; Gauthier-Villars M; Jernstrom H; Sun P; Brunet JS
    J Natl Cancer Inst; 2002 Dec; 94(23):1773-9. PubMed ID: 12464649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
    Couch FJ; Gaudet MM; Antoniou AC; Ramus SJ; Kuchenbaecker KB; Soucy P; Beesley J; Chen X; Wang X; Kirchhoff T; McGuffog L; Barrowdale D; Lee A; Healey S; Sinilnikova OM; Andrulis IL; ; Ozcelik H; Mulligan AM; Thomassen M; Gerdes AM; Jensen UB; Skytte AB; Kruse TA; Caligo MA; von Wachenfeldt A; Barbany-Bustinza G; Loman N; Soller M; Ehrencrona H; Karlsson P; ; Nathanson KL; Rebbeck TR; Domchek SM; Jakubowska A; Lubinski J; Jaworska K; Durda K; Zlowocka E; Huzarski T; Byrski T; Gronwald J; Cybulski C; Górski B; Osorio A; Durán M; Tejada MI; Benitez J; Hamann U; Hogervorst FB; ; van Os TA; van Leeuwen FE; Meijers-Heijboer HE; Wijnen J; Blok MJ; Kets M; Hooning MJ; Oldenburg RA; Ausems MG; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Jacobs C; Eeles RA; Adlard J; Davidson R; Eccles DM; Cole T; Cook J; Paterson J; Brewer C; Douglas F; Hodgson SV; Morrison PJ; Walker L; Porteous ME; Kennedy MJ; Side LE; ; Bove B; Godwin AK; Stoppa-Lyonnet D; ; Fassy-Colcombet M; Castera L; Cornelis F; Mazoyer S; Léoné M; Boutry-Kryza N; Bressac-de Paillerets B; Caron O; Pujol P; Coupier I; Delnatte C; Akloul L; Lynch HT; Snyder CL; Buys SS; Daly MB; Terry M; Chung WK; John EM; Miron A; Southey MC; Hopper JL; Goldgar DE; Singer CF; Rappaport C; Tea MK; Fink-Retter A; Hansen TV; Nielsen FC; Arason A; Vijai J; Shah S; Sarrel K; Robson ME; Piedmonte M; Phillips K; Basil J; Rubinstein WS; Boggess J; Wakeley K; Ewart-Toland A; Montagna M; Agata S; Imyanitov EN; Isaacs C; Janavicius R; Lazaro C; Blanco I; Feliubadalo L; Brunet J; Gayther SA; Pharoah PP; Odunsi KO; Karlan BY; Walsh CS; Olah E; Teo SH; Ganz PA; Beattie MS; van Rensburg EJ; Dorfling CM; Diez O; Kwong A; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ditsch N; Arnold N; Heidemann S; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Fiebig B; Heinritz W; Caldes T; de la Hoya M; Muranen TA; Nevanlinna H; Tischkowitz MD; Spurdle AB; Neuhausen SL; Ding YC; Lindor NM; Fredericksen Z; Pankratz VS; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Barile M; Bernard L; Viel A; Giannini G; Varesco L; Radice P; Greene MH; Mai PL; Easton DF; Chenevix-Trench G; ; Offit K; Simard J;
    Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):645-57. PubMed ID: 22351618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.